They just lost the contract. Whoever wrote the proposal did a poor job or NIH was not impressed with what they had done with the last contract, or money is just tight and this was not a high enough priority.
"We are currently developing diagnostic products to detect the Lassa virus (LASV), Junin virus (JUNV), Ebola virus (EBOV) and Marburg virus (MARV), all very important pathogens. Through our consortium we are also in early development of additional products for Dengue virus (DENV), Chikungunya virus (CHIKV), Crimean-Congo virus (CCHV) and others. Our infectious disease products will be used not only in clinical laboratories but also in point-of-care testing in the field. The first of these products to be completed is the Rapid Test for detection of Lassa hemorrhagic fever. It is in final clinical studies and will be submitted to the FDA in 2012."